Skip to main content

Table 1 Patient characteristics

From: Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT

Characteristics All Radical RT group Salvage RT group Oligomts RT group
Patient groups     
Patients (n) 43 21 17 5
Age (years), (range) 70 (58–84) 72 (65–81) 69 (58–84) 68 (65–71)
Gleason score     
6–7 24 14 8 2
8–9 18 7 8 3
TNM stage     
Tx 3 2 1 3
T1-2 25 9 11 2
T3-4 18 10 5 2
N0/x 38 20 16 3
N1-2 5 1 1 3
M0/x 41 21 17 2
M1 2  
Initial PSA (ng/ml) median (range) 28.4 (6.3–530) 52.3 (11–530) 10.4 (6.3–21) 22.6 (6.9–52)
PSA pre PSMA-PET/CT (ng/ml) median (range) 4.34 (0.1–30.6) 9.4 (0.2–30.6) 2.8 (0.1–21.8) 0.8 (0.1–1.9)
ADT at time of PET 27 21 1 5
PSMA-PET/CT revealed metastases (LN, Bones, FR) 30 11 15 4
Lymph nodes 10 4 7 1
Bones 6 3 1 2
Lymph nodes and bones 5 4 1
FR (FR + nodes) 6 (1) 6 (1)
  1. PSA, prostate-specific antigen; PSMA, PET/CT prostate-specific membrane antigen positron emission tomography/computed tomography; ADT, androgen deprivation therapy; LNs, lymph nodes; FR,fossa recurrence; RT, radiation therapy; Oligomts, oligometastatic; Salvage RT, post-prostatectomy RT